Biotechnology Company
Appears in 1 story
Developer of zorevunersen; leading the Phase 3 EMPEROR trial
Dravet syndrome is a severe genetic epilepsy that causes hundreds of seizures per month, cognitive decline, and a 15–20 percent mortality rate. For nearly five decades, no treatment addressed the underlying cause — including two drugs approved in the past eight years, which could only partially suppress symptoms.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
